OptiBiotix Health (LSE:OPTI) is shifting its focus towards commercialising SweetBiotix, its sugar-substitute fibre, after reporting higher first-half revenue and improved gross margins but a wider pre-tax loss. The half-year report, published on 17 September 2026, followed a SweetBiotix update earlier that month in which the company said lab-scale samples had begun shipping to food, beverage and confectionery companies, including a major global beverage firm.
What the company does
OptiBiotix is a life sciences company developing products that aim to reduce hunger and cravings, support the gut microbiome and replace sugar with sweet fibres. Its first-generation products include SlimBiome, used in weight management, and WellBiome, aimed at gut and digestive health. SweetBiotix is its second-generation product. The company also holds an investment in skin health business SkinBioTherapeutics.
Latest developments
In its 8 September update, OptiBiotix said independent testing at the University of Reading's Flavour and Sensory Science Centre found SweetBiotix to be about 100 times sweeter than sugar with a clean taste. An enzyme development announced in November 2025 enables a one-step production process that the company says improves yields and purity while lowering costs. The company added that structural analysis had confirmed a modified prebiotic structure, which it believes supports its patent filings. Negotiations are under way with three manufacturers, and the company is targeting initial manufactured samples around the end of 2026, subject to agreements and production schedules.
There has been progress on the first-generation range too. On 2 September, Holland & Barrett launched an own-label product, FORMI, containing SlimBiome, and the company announced a US trademark licence after the period end. In September OptiBiotix also announced directorate changes at its OptiBiotix Ltd subsidiary, and chief executive Stephen O'Hara highlighted the sweetener expertise of new non-executive director Imad Farhat.
Financial picture
Revenue for the six months to 30 June 2026 rose 21.9% to £679,000 from £557,000, and gross margin improved to 55.9% from 54.4%. The operating loss was £753,000, while the loss before tax widened to £1.6 million from £1.18 million, affected by a £554,000 loss on disposal of investments and a £320,000 fair value loss. The company sold part of its holding in SkinBioTherapeutics in May 2026, and total investments were valued at £640,000 at the period end. Cash was £0.99 million, with no debt and net assets of £4.73 million. No dividend is paid.
Sector and index context
OptiBiotix is a small constituent of the FTSE AIM All Share Index operating in the functional food and ingredients space. Demand for sugar alternatives and gut health products remains a theme for the food industry, but the company has noted that the spread of cheaper generic GLP-1 weight-loss medicines has hit demand in some markets.
Key risks
Several headwinds were flagged in the interim report. US sales were hurt by a customer's restructuring, sales in India fell to £3,000 from £114,000 as generic GLP-1 drugs spread, and its relationship with a Chinese trading partner has been suspended. With a cash balance of under £1 million, funding is a consideration, and SweetBiotix still needs to reach commercial-scale manufacturing and secure customer agreements.
What to watch next
Management has said its priority for the second half of 2026 is to accelerate commercialisation of the second-generation portfolio, with SweetBiotix at the centre. Investors will look for manufacturing agreements, feedback from companies testing samples, the delivery of initial manufactured samples around the year end and further cost savings expected in the second half.






Please wait processing your request...